{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-087110","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2026-07-27T20:35:10+00:00","discovered_at":"2026-07-27T20:36:20.071298+00:00","generated_at":"2026-07-27T20:36:26.409496+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"SELLAS loses arbitration against 3D Medicines; cash $138.3M as of June 30","bullets":["Arbitration claims dismissed; company ordered to pay ~$1.0M in legal fees.","3D Medicines to continue GPS development; $191.5M in potential milestones remain, including $13.0M disputed.","Preliminary unaudited cash and equivalents $138.3M as of June 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-087110","json":"https://secwatch.observer/filing/0001104659-26-087110.json","markdown":"https://secwatch.observer/filing/0001104659-26-087110.md","text":"https://secwatch.observer/filing/0001104659-26-087110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465926087110/0001104659-26-087110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465926087110/tm2621415d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-27T20:36:26.409496+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}